Myasthenia Gravis Therapeutic Benefits Of Monotherapy With Tacrolimus Overview In the management of mild to moderate myasthenia gravis (MG), the utilization of tacrolimus is typically reserved for cases that do not respond to glucocorticoids. This study sought to assess the potential advantages of mono-tacrolimus over mono-glucocorticoids in treating MG patients. The primary endpoint
Tag: Adverse Events in MG
